Reporting of screening results
In a recent leader, 1 Wald and Dormandy discussed the reporting of screening test results and concluded that reporting results as screen positive or screen negative is better than the various alternatives. For Down's syndrome screening we would strongly disagree with this view. When we started second trimester biochemical screening for Down's syndrome the consensus view of both obstetricians and clinical biochemists providing the analysis was that the actual risk estimate should be reported. After eight years' experience of screening we remain of this view.
It is important to make a distinction between a screening test such as a mammogram in screening for breast cancer, where the consequences of a true positive are suYciently serious to warrant a diagnostic test in all positive screens, and screening for Down's syndrome, where many would consider having an aVected baby to be undesirable but are prepared to accept this as a possible outcome. Anyone undergoing Down's syndrome screening after adequate counselling would be very anxious if their risk was 1 in 5, whereas lower risks may be viewed diVerently by individual women. Amniocentesis or chorionic villus sampling (CVS) both carry a risk of miscarriage and an older woman anxious to avoid a miscarriage may consider a risk of 1 in 100 as acceptable, whereas others (often younger), may be anxious to avoid having a child with Down's syndrome and wish to have an amniocentesis when the risk is 1 in 300.
A policy of reporting screen negative or screen positive has no regard for the individual patient as it denies them the chance to discuss their own circumstances with their doctor or midwife. An arbitrary cut oV point, commonly 1 in 250 is used, in which case 1 in 5 and 1 in 250 would both be reported as screen positive, whereas 1 in 300 would be reported as screen negative. It was claimed that reporting the risk estimate makes the screening process relatively unpredictable, as a screening policy should oVer a diagnostic test only to those found to be at greatest risk on the grounds of hazard or cost. However, in our experience, this policy allows far greater individual decision making and still results in a diagnostic procedure in a high percentage of those at greatest risk (table 1) , while only a small percentage (0.15%) of patients with a low risk of less than 1 in 400 and a normal ultrasound scan had an amniocentesis. Reporting screen positive or screen negative results removes all elements of individual choice.
The performance of the screening programme can readily be audited by taking an arbitrary cut oV point, in the same way as in defining the cut oV point of a screen negative test (for example, 1 in 250), or by taking a cut oV point representing a fixed false positive rate, to determine the number of true positives and false negatives each year. The uptake of diagnostic testing is also easily calculated from information provided by the cytogenetics department(s) receiving the amniocentesis and CVS samples.
Our conclusion is that health professionals cannot provide clear information and guidance to women undergoing Down's syndrome screening without knowing the actual Down's syndrome risk estimate. It is inadequate simply to explain that screen positive does not mean that the disorder is present, or the converse, often more diYcult for patients to understand, that a screen negative result does not mean that it is definitely absent. Reporting of the Down's syndrome risk estimate together with the appropriate education of clinicians and good communication between them and the laboratory can provide the best service to individual patients. 
Authors' reply
Beaman and her colleagues may have misunderstood our editorial. 1 We did not say that individual risk estimates should not be given. Quite the reverse, we have always recommended this for women with screen positive results. Our standard computer generated reports not only categorise results as screen positive or negative but they also automatically report the individual risk estimates for screen positives; an example is given in fig  12. 9 of reference 2. 2 There is also the option of giving risk estimates for women with screen negative results if screening units so choose.
It is the proposal that the categories of screen positive and screen negative be abolished that we were arguing against, not that individual risk estimates should be withheld. We do not see that there is a fundamental distinction between a screen positive and screen negative result when screening for Down's syndrome, neural tube defects, breast cancer, or other disorders. Of course, if the odds of being aVected given a positive result (OAPR) are high, most individuals will choose to have a diagnostic test; if the OAPR is low they may choose otherwise. The decision will depend on many factors, including the risk of the diagnostic procedure, the probability of being aVected, and the nature of the disorder being screened for.
The results Beaman and her colleagues tabulate on the percentage of women undergoing amniocentesis or chorionic villus sampling (CVS) according to the reported estimate of Down's syndrome pregnancies is of interest. It shows, as others have shown, that women respond in a rational manner to their risk. What is perhaps surprising is that with risks of 1 in 300 or less, the uptake of amniocentesis or CVS falls strikingly compared with higher risks. The pattern is clearly discontinuous at a risk of 1 in 300. It would seem that some guidance or diVerential reporting had been oVered to the women. Having no line of distinction would mean that there was an obligation to provide an amniocentesis or CVS whatever a person's individual risk, and while clinicians will of course use discretion in such matters, it is widely believed that oVering an invasive diagnostic test regardless of the risk of Down's syndrome is not an appropriate population screening strategy.
Provided that individual risk estimates are used as well as categorising screening results as positive or negative in screening reports, it would seem that there is no diVerence between our views and the views of Beaman and her colleagues. 
